Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control

doi:10.19982/j.issn.1000-6621.20240316

Abstract

Abstract:

The control of drug-resistant tuberculosis (TB) globally still faces huge challenges. The PAN-TB regimen is a first-line regimen suitable for all forms of TB, which means that it should be initiated immediately upon confirmation of active TB disease, without waiting for the patient’s drug resistance status. The goal of implementing the PAN-TB regimen is to initiate effective treatment as soon as possible, reduce transmission, and significantly simplify the complexity of TB program management. It is not only a clinical treatment method, but also a public health measure. This article defines the definition, requirements, global research progress, and significance for TB control of the PAN-TB strategy, with the aim of providing new ideas for the prevention and control of TB in China.

Key words: Tuberculosis, Antitubercular agents, Therapeutic uses, Program evaluation

CLC Number:

Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192. doi: 10.19982/j.issn.1000-6621.20240316

Figures/Tables 1

参数	最低配置		最高配置
参数	2016年	2023年	2016年	2023年
指征	一线治疗方案,不需要确定利福平是否耐药	包括利福平敏感结核病和利福平耐药结核病在内的活动性结核病患者的一线治疗	一线治疗方案,不需要确定利福平是否耐药	包括利福平敏感结核病和利福平耐药结核病在内的活动性结核病患者的一线治疗
疗效	不劣于利福平敏感结核病,疗程6个月	疗效与利福平敏感结核病标准治疗相当的方案,疗程3~4个月	不劣于利福平敏感结核病,疗程4个月	疗效优于利福平敏感结核病标准治疗方案,疗程≤2个月
安全性和耐受性	不良事件的发生率和严重程度不高于标准方案。除特殊人群(已患肝病和糖尿病等)外,每月对不良反应进行实验室监测不超过1次	不良事件的发生率和严重程度低于利福平敏感结核病的标准治疗。除特定人群(已患肝肾疾病和糖尿病等)外,每月不超过1次对药物毒性的临床和实验室监测。耐受性应优于利福平敏感结核病的标准治疗方案	不良事件的发生率和严重程度优于标准方案。除特殊人群(已患肝病和糖尿病等)外,无需进行主动的不良反应监测。无需监测QT间期	不良事件的发生率和严重程度应低于利福平敏感结核病的标准治疗方案。除特定人群(已患肝、肾疾病和糖尿病等)外,无需对药物毒性进行积极的临床监测和实验室监测。耐受性应优于利福平敏感结核病的标准治疗方案
药物相互作用与代谢	需要针对药物相互作用进行剂量调整或安全性监测,包括:至少1种一线抗逆转录病毒治疗药物、诱导或抑制细胞色素P450肝酶的药物、致QT延长药物	无	其他药物无需调整剂量,同时无需对以下药物主动进行药物相互作用监测:抗逆转录病毒治疗药物与复方新诺明、诱导或抑制细胞色素P450肝酶的药物、致QT延长药物	无
发生耐药性的可能(产生耐药性的倾向或存在交叉耐药性)	方案中每种药物的突变率(在未选择的细菌群体中)每种细菌每代不应大于1/10⁷;治疗时对方案中的1种或多种药物的新耐药率低于2%,并且治疗前对药物不存在耐药性	在1种或多种药物的治疗过程中或治疗后获得或扩大耐药性的可能不高于标准治疗方案	方案中每种药物的突变率(在未选择的细菌群体中)每种细菌每代不应大于1/10⁹;治疗后,基本上没有获得性耐药(耐药率<0.1%),并且治疗前对方案中的药物不存在耐药性	在1种或多种药物的治疗过程中或治疗后获得或扩大耐药性的可能低于标准治疗方案
服药负荷	无	不大于当前的利福平敏感结核病标准治疗方案	无	成人剂量1片/d

References 25

[1]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis-rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organi-zation, 2024.
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[3]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[4]	World Health Organization. Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicin-resistant and pan-TB treatment regimens. Geneva: World Health Organization, 2016.
[5]	Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol, 2022, 20(11):685-701. doi:10.1038/s41579-022-00731-y. pmid: 35478222
[6]	Paton NI, Cousins C, Suresh C, et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. N Engl J Med, 2023, 388(10):873-887. doi:10.1056/NEJMoa2212537.
[7]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi:10.1056/NEJMoa1901814.
[8]	Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med, 2022, 387(9):810-823. doi:10.1056/NEJMoa2119430.
[9]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2):117-128. doi:10.1016/S2213-2600(23)00389-2.
[10]	World Health Organization. Target regimen profiles for tuberculosis treatment, 2023 update. Geneva: World Health Organization, 2024.
[11]	Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993. doi:10.1016/S0140-6736(12)61080-0. pmid: 22828481
[12]	Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med, 2015, 191(8):943-953. doi:10.1164/rccm.201410-1801OC.
[13]	Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet, 2015, 385(9979):1738-1747. doi:10.1016/S0140-6736(14)62002-X. pmid: 25795076
[14]	Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med, 2019, 7(12):1048-1058. doi:10.1016/S2213-2600(19)30366-2. pmid: 31732485
[15]	Cevik M, Thompson LC, Upton C, et al. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis, 2024, 17: S1473- 3099(24)00223-8. doi:10.1016/S1473-3099(24)00223-8.
[16]	Almeida D, Converse PJ, Li SY, et al. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother, 2021, 65(12):e0141221. doi:10.1128/AAC.01412-21.
[17]	Tasneen R, Betoudji F, Tyagi S, et al. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Beda-quiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother, 2015, 60(1):270-277. doi:10.1128/AAC.01691-15.
[18]	Hariguchi N, Chen X, Hayashi Y, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother, 2020, 64(6):e02020-19. doi:10.1128/AAC.02020-19.
[19]	Tenero D, Derimanov G, Carlton A, et al. First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. Antimicrob Agents Chemother, 2019, 63(8):e00240-19. doi:10.1128/AAC.00240-19.
[20]	Brown KL, Wilburn KM, Montague CR, et al. Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. Antimicrob Agents Chemother, 2023, 67(1): e0129422. doi:10.1128/aac.01294-22.
[21]	Wallis RS, Cohen T, Menzies NA, et al. Pan-tuberculosis regimens: an argument for. Lancet Respir Med, 2018, 6(4):239-240. doi:10.1016/S2213-2600(18)30096-1.
[22]	Dheda K, Gumbo T, Lange C, et al. Pan-tuberculosis regimens: an argument against. Lancet Respir Med, 2018, 6(4):240-242. doi:10.1016/S2213-2600(18)30097-3. pmid: 29595502
[23]	Gupta R, Wells CD. Pan-tuberculosis regimens: re-framing the argument. Lancet Respir Med, 2018, 6(7):e28. doi:10.1016/S2213-2600(18)30189-9. pmid: 29976444
[24]	Arinaminpathy N, Gomez GB, Sachdeva KS, et al. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis. PLoS One, 2020, 15(3):e0230808. doi:10.1371/journal.pone.0230808.
[25]	Kendall EA, Brigden G, Lienhardt C, et al. Would pan-tuberculosis treatment regimens be cost-effective?. Lancet Respir Med, 2018, 6(7):486-488. doi:10.1016/S2213-2600(18)30197-8. pmid: 29859919